home / stock / aktx / aktx quote
Last: | $1.185 |
---|---|
Change Percent: | 0.42% |
Open: | $1.185 |
Close: | $1.185 |
High: | $1.2 |
Low: | $1.17 |
Volume: | 10,002 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.185 | $1.185 | $1.185 | $1.2 | $1.17 | 10,002 | 04-26-2024 |
$1.19 | $1.2 | $1.19 | $1.2 | $1.17 | 3,902 | 04-25-2024 |
$1.19 | $1.21 | $1.19 | $1.21 | $1.1701 | 7,532 | 04-24-2024 |
$1.21 | $1.13 | $1.21 | $1.235 | $1.13 | 4,786 | 04-23-2024 |
$1.18 | $1.13 | $1.18 | $1.22 | $1.13 | 13,919 | 04-22-2024 |
$1.1662 | $1.11 | $1.1662 | $1.2 | $1.0805 | 3,740 | 04-19-2024 |
$1.21 | $1.14 | $1.21 | $1.225 | $1.11 | 8,776 | 04-18-2024 |
$1.1212 | $1.1 | $1.1212 | $1.2383 | $1.0775 | 7,933 | 04-17-2024 |
$1.1555 | $1.2 | $1.1555 | $1.25 | $1.136 | 14,524 | 04-16-2024 |
$1.2 | $1.23 | $1.2 | $1.2699 | $1.2 | 9,109 | 04-15-2024 |
$1.21 | $1.21 | $1.21 | $1.27 | $1.21 | 28,156 | 04-12-2024 |
$1.1 | $1.3001 | $1.1 | $1.4 | $1.1 | 37,351 | 04-11-2024 |
$1.3 | $1.2001 | $1.3 | $1.33 | $1.19 | 11,273 | 04-10-2024 |
$1.315 | $1.41 | $1.315 | $1.49 | $1.265 | 7,481 | 04-09-2024 |
$1.4 | $1.42 | $1.4 | $1.5 | $1.2 | 5,390 | 04-08-2024 |
$1.41 | $1.45 | $1.41 | $1.53 | $1.41 | 3,798 | 04-05-2024 |
$1.44 | $1.53 | $1.44 | $1.58 | $1.4301 | 27,922 | 04-04-2024 |
$1.55 | $1.51 | $1.55 | $1.5796 | $1.51 | 14,093 | 04-03-2024 |
$1.51 | $1.53 | $1.51 | $1.555 | $1.51 | 8,244 | 04-02-2024 |
$1.51 | $1.85 | $1.51 | $1.85 | $1.5 | 111,812 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
BOSTON and LONDON, April 15, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will present new pre-clinical data on investigational long-acting PAS-nomacopan...
BOSTON and LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights. ...
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potenti...